½ÃÀ庸°í¼­
»óǰÄÚµå
1518360

Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç° À¯Çüº°, ´ç´¢º´ À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(-2030³â)

Blood Glucose Monitoring Devices Market by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Receiver, Transmitter}), Diabetes Type, End User (Self/Home Care, Hospital, Clinic) - Global Forecast to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Meticulous Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 5-7ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº 2023-2030³â°£ 7.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 217¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­´Â Á¾ÇÕÀûÀÎ 1Â÷ ¹× 2Â÷ Á¶»ç, ½ÃÀå ½Ã³ª¸®¿À¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®¿¡ À̾î ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ ¹× °úÁ¦¿¡ ´ëÇÑ ºÐ¼®À» ´ã°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ´ç´¢º´ À¯º´·ü Áõ°¡, °Ç°­¿¡ ÁÁÁö ¾ÊÀº ÁÂ½Ä »ýȰ½À°üÀ» °¡Áø Àα¸ Áõ°¡, ´ç´¢º´ Ä¡·áÀÇ Á¦Ç° Çõ½Å¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª º¸Çè Àû¿ë ¹× »óȯÀÇ ºÒÈ®½Ç¼º, Á¦Ç° ¸®ÄÝ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ºñħ½ÀÀû Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ½ÅÈï±¹ÀÇ ´ç´¢º´ °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª Áø´ÜµÇÁö ¾ÊÀº ´ç´¢º´ ȯÀÚ ¼ö°¡ ¸¹°í ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ±â±âÀÇ °íºñ¿ëÀº ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Å« µµÀü °úÁ¦ÀÔ´Ï´Ù.

Á¦Ç°º°·Î´Â ÀÚ°¡ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ºÎ¹®ÀÌ 2023³â Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ³ôÀº ½ÃÀå Á¡À¯À²Àº ³ôÀº 2Çü ´ç´¢º´ À¯º´·ü, Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¿¡ »ç¿ëµÇ´Â Å×½ºÆ® ½ºÆ®¸³¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä, ´ç´¢º´ ÀÚ°¡ °ü¸®¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

´ç´¢º´ À¯Çüº°·Î º¸¸é, 2023³â¿¡´Â 2Çü ´ç´¢º´ ºÎ¹®ÀÌ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ Å« ½ÃÀå Á¡À¯À²Àº ½Åü Ȱµ¿·®ÀÌ Àû°í °Ç°­¿¡ ÇØ·Î¿î »ýȰ ½À°üÀ» °¡Áø »ç¶÷µéÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦ 2Çü ´ç´¢º´ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é, 2023³â¿¡´Â ÀÚ°¡ °ü¸®/ÀçÅÃÄ¡·á ºÎ¹®ÀÌ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹® ½ÃÀå Á¡À¯À²ÀÌ Å« ÀÌÀ¯´Â ÆíÀǼº, ºñ¿ë È¿À²¼º µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ´ç´¢º´ ÀÚ°¡ °ü¸®¸¦ À§ÇØ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¸¦ »ç¿ëÇϴ ȯÀÚ Àα¸°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.

2023³â¿¡´Â ºÏ¹Ì°¡ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, À¯·´°ú ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ±× µÚ¸¦ ÀÌÀ» °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ºÏ¹ÌÀÇ ³ôÀº ½ÃÀå ±Ô¸ð´Â ´ç´¢º´ °ü¸®¿¡ ´ëÇÑ ³ôÀº ÀνÄ, ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ°ú °°Àº ½Å±â¼úÀÇ ³ôÀº äÅ÷ü, ÀÌ Áö¿ª Àα¸ÀÇ ³ôÀº ±¸¸Å·Â µî¿¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
  • Á¶»çÀÇ ÇѰè

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå °³¿ä
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • °úÁ¦
  • COVID-19ÀÇ ¼¼°è Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
  • ±ÔÁ¦ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç°º°

  • ¼­·Ð
  • ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â
    • Ç÷´ç ÃøÁ¤±â
    • ½ÃÇè ½ºÆ®¸³
    • ¶õ¼Â
  • Áö¼Ó Ç÷´ç ÃøÁ¤±â
    • ¼¾¼­
    • Æ®·£½º¹ÌÅÍ ¹× ¸®½Ã¹ö
  • ±âŸ ±â±â ¹× ºÎ¼Óǰ

Á¦6Àå ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ´ç´¢º´ À¯Çüº°

  • ¼­·Ð
  • 2Çü ´ç´¢º´
  • 1Çü ´ç´¢º´
  • ÀӽŠ´ç´¢º´

Á¦7Àå ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • Àڱ⠰ǰ­ °ü¸®/ÀçÅÃÄ¡·á
  • º´¿ø ¹× Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ÁÖ¿ä ¼ºÀå Àü·«
  • °æÀï ´ë½Ãº¸µå
  • º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
  • ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â)

Á¦10Àå ±â¾÷ °³¿ä(»ç¾÷ °³¿ä, À繫 °³¿ä, Á¦Ç° °³¿ä, Àü·«Àû Àü°³)

  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings AG
  • Becton, Dickinson and Company
  • DexCom, Inc.
  • F. Hoffmann-La Roche Ltd.
  • LifeScan IP Holdings, LLC
  • Medtronic plc
  • Ypsomed Holding AG
  • B. Braun Melsungen AG
  • Nipro Corporation
  • ARKRAY, Inc.
  • Prodigy Diabetes Care, LLC
  • ACON Laboratories, Inc.
  • Nova Biomedical Corporation
  • Other Companies

Á¦11Àå ºÎ·Ï

LSH 24.07.30

Blood Glucose Monitoring Devices Market Size, Share, Forecast, & Trends Analysis by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Transmitter}), Diabetes Type, End User- Global Forecast to 2030

The blood glucose monitoring devices market is projected to reach $21.71 billion by 2030, at a CAGR of 7.5% from 2023 to 2030.

Following comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides an analysis of the key market drivers, restraints, opportunities, and challenges. This market is driven by the rising prevalence of diabetes, the increasing number of people living unhealthy & sedentary lifestyles, and product innovations in diabetes care. However, insurance coverage and reimbursement uncertainties and product recalls restrain the growth of this market.

Furthermore, the growing demand for non-invasive glucose monitoring devices and increasing awareness regarding diabetic health in developing countries are expected to generate significant growth opportunities for the players in this market. However, the large number of people living with undiagnosed diabetes and the high costs of continuous glucose monitoring devices are major challenges impacting market growth.

Based on product, in 2023, the self-monitoring devices segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to factors such as the high prevalence of Type-2 diabetes, the recurring demand for test strips used with blood glucose monitoring devices, and increased awareness about diabetes self-management.

Based on diabetes type, in 2023, the Type-2 diabetes segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the increased prevalence of Type-2 diabetes due to the increasing number of people living unhealthy lifestyles without physical activity.

Based on end user, in 2023, the self/home care segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the large patient population utilizing blood glucose monitoring devices for the self-management of diabetes due to their advantages, such as convenience and cost-effectiveness.

In 2023, North America is expected to account for the largest share of the blood glucose monitoring devices market, followed by Europe and Asia-Pacific. North America's large market is attributed to the high awareness regarding diabetes management, high adoption of newer technologies such as continuous glucose monitoring, and higher purchasing power of the population in the region.

The key players operating in the blood glucose monitoring devices market are Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (a subsidiary of PHC Holdings Corporation) (Switzerland), Becton, Dickinson and Company (U.S.), DexCom, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), LifeScan IP Holdings, LLC (a subsidiary of Platinum Equity, LLC, U.S.) (Switzerland), Medtronic plc (Ireland), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Nipro Corporation (Japan), ARKRAY, Inc. (U.S.), Prodigy Diabetes Care, LLC (U.S.), ACON Laboratories, Inc. (U.S.), and Nova Biomedical Corporation (U.S.).

Scope of the Report:

Blood Glucose Monitoring Devices Market Assessment-by Product

  • Self-monitoring Devices
    • Blood Glucose Meters
    • Test Strips
    • Lancets
  • Continuous Blood Glucose Monitoring Devices
    • Sensors
    • Transmitters & Receivers
  • Other Devices & Accessories

Note: Other devices & accessories include hemoglobin A1c testing kits and non-invasive blood glucose monitoring devices.

Blood Glucose Monitoring Devices Market Assessment-by Diabetes Type

  • Type-2 Diabetes
  • Type-1 Diabetes
  • Gestational Diabetes

Blood Glucose Monitoring Devices Market Assessment-by End User

  • Self/Home Care
  • Hospital & Clinics
  • Other End Users

Note: Other end users include physician offices, ambulatory care settings, and diagnostics labs.

Blood Glucose Monitoring Devices Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Indonesia
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-up Approach
      • 2.3.1.2. Top-down Approach
      • 2.3.1.3. Growth Forecast
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Prevalence of Diabetes
    • 4.2.2. Increasing Number of People Living Unhealthy & Sedentary Lifestyles
    • 4.2.3. Product Innovations in Diabetes Care
  • 4.3. Restraints
    • 4.3.1. Insurance Coverage and Reimbursement Scenarios
    • 4.3.2. Product Recalls
  • 4.4. Opportunities
    • 4.4.1. Growing Demand for Non-Invasive Glucose Monitoring Devices
    • 4.4.2. Increasing Awareness About Diabetic Health in Developing Countries
  • 4.5. Challenges
    • 4.5.1. Large proportion of People With Undiagnosed Diabetes
    • 4.5.2. High Costs of Continuous Glucose Monitoring Devices
  • 4.6. The Impact of COVID-19 on the Global Blood Glucose Monitoring Devices Market
  • 4.7. Regulatory Analysis

5. Global Blood Glucose Monitoring Devices Market, by Product

  • 5.1. Introduction
  • 5.2. Self-monitoring Devices
    • 5.2.1. Blood Glucose Meters
    • 5.2.2. Test Strips
    • 5.3.3. Lancets
  • 5.3. Continuous Blood Glucose Monitoring Devices
    • 5.3.1 Sensors
    • 5.3.2 Transmitters & Receivers
  • 5.4. Other Devices & Accessories

6. Global Blood Glucose Monitoring Devices Market, by Diabetes Type

  • 6.1. Introduction
  • 6.2. Type-2 Diabetes
  • 6.3. Type-1 Diabetes
  • 6.4. Gestational Diabetes

7. Global Blood Glucose Monitoring Devices Market, by End User

  • 7.1. Introduction
  • 7.2. Self/Home Care
  • 7.3. Hospital & Clinics
  • 7.4. Other End Users

8. Blood Glucose Monitoring Devices Market, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe (RoE)
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Indonesia
    • 8.4.4. Rest of Asia-Pacific (RoAPAC)
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Argentina
    • 8.5.4. Rest of Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Dashboard
  • 9.4. Vendor Market Positioning
  • 9.5. Market Share Analysis (2022)

10. Company Profiles (Business Overview, Financial Overview, Product Overview, Strategic Developments)

  • 10.1. Abbott Laboratories
  • 10.2. Ascensia Diabetes Care Holdings AG
  • 10.3. Becton, Dickinson and Company
  • 10.4. DexCom, Inc.
  • 10.5. F. Hoffmann-La Roche Ltd.
  • 10.6. LifeScan IP Holdings, LLC
  • 10.7. Medtronic plc
  • 10.8. Ypsomed Holding AG
  • 10.9. B. Braun Melsungen AG
  • 10.10. Nipro Corporation
  • 10.11. ARKRAY, Inc.
  • 10.12. Prodigy Diabetes Care, LLC
  • 10.13. ACON Laboratories, Inc.
  • 10.14. Nova Biomedical Corporation
  • 10.15. Other Companies

11. Appendix

  • 11.1. Questionnaire
  • 11.2. Available Customization
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦